Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

VICORE PHARMA Aktie

 >VICORE PHARMA Aktienkurs 
0.944 EUR    (TradegateBSX)
Ask: 0.953 EUR / 1200 Stück
Bid: 0.935 EUR / 1200 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>VICORE PHARMA Performance
1 Woche: +5,7%
1 Monat: +3,2%
3 Monate: -7,4%
6 Monate: -18,8%
1 Jahr: +46,8%
laufendes Jahr: -10,8%
>VICORE PHARMA Aktie
Name:  VICORE PHARMA HOLDING AB
Land:  Schweden
Sektor:  Gesundheit
ISIN/ Wkn:  SE0007577895 / A14W4W
Symbol/ Ticker:  6Y4 (Frankfurt)
Kürzel:  FRA:6Y4, ETR:6Y4, 6Y4:GR
Index:  -
Webseite:  https://vicorepharma.com/
Profil:  Vicore Pharma Holding AB is a clinical-stage pharmaceutical company based in Sweden, specializing in the development of innovative therapies targeting severe respiratory and fibrotic diseases, particularly through angiotensin II type 2 receptor agoni..
>Volltext..
Marktkapitalisierung:  273 Mio. EUR
Unternehmenswert:  165.57 Mio. EUR
Umsatz:  0.36 Mio. EUR
EBITDA:  -42.6 Mio. EUR
Nettogewinn:  -44.76 Mio. EUR
Gewinn je Aktie:  -0.19 EUR
Schulden:  -
Liquide Mittel:  54.19 Mio. EUR
Operativer Cashflow:  -35.22 Mio. EUR
Bargeldquote:  9.85
Umsatzwachstum:  -96.3%
Gewinnwachstum:  -200.03%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  VICORE PHARMA
Letzte Datenerhebung:  06.04.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 281.53 Mio. St.
Frei handelbar: 64.46%
Leerverk. Aktien: -
Rückkaufquote: -14.78%
Mitarbeiter: 37
Umsatz/Mitarb.: 0.01 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 183.28%
Bewertung:
KGV: -
KGV lG: -
KUV: 684.9
KBV: 2.4
PEG-Ratio: -0.07
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -12509.14%
Operative Marge: -11905.82%
Managementeffizenz:
Gesamtkaprendite: -39.43%
Eigenkaprendite: -42.92%
>Peer Group
Gesundheit, Neurologische- & psychische Behandlung/ Medizin, Medizinprodukte & -technik/ Implantate/ Wundpflege
 
01.04.26 - 09:30
Notice Of Annual General Meeting In Vicore Pharma Holding AB (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / April 1, 2026 / The shareholders of Vicore Pharma Holding AB (publ)(STO:VICO), reg. no. 556680-3804 (the "Company"), are summoned to the Annual General Meeting on ......
26.03.26 - 08:30
Vicore Pharma Holding: Vicore Publishes the Annual Report for 2025 (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / March 26, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today an......
09.03.26 - 08:30
Vicore Pharma Holding: Vicore Pharma to Present at Upcoming Investor Conferences (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / March 9, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today ann......
05.03.26 - 08:30
Vicore Pharma Holding: Vicore Pharma Elevates Leadership Team Ahead of Key Clinical and Corporate Milestones (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / March 5, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAG......
27.02.26 - 08:30
Vicore Pharma Holding: Year-End Report 2025 (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / February 27, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (A......
26.02.26 - 08:30
Vicore Pharma Holding: Vicore Pharma to Present at Upcoming Investor Conferences (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor a......
18.02.26 - 08:30
Vicore Pharma Holding: Vicore Pharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / February 18, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor a......
07.01.26 - 08:30
Vicore Pharma Holding: Vicore Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / January 7, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor ago......
19.12.25 - 08:36
Vicore Pharma Holding: Vicore Pharma To Move To The Nasdaq Stockholm Mid Cap Segment (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / December 19, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs)......
05.12.25 - 08:30
Vicore Pharma Holding: Vicore to Present at the Oppenheimer Movers in Rare Disease Summit (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / December 5, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs),......
28.11.25 - 09:39
Vicore Pharma Holding: Increase in Number of Shares and Votes in Vicore Pharma (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / November 28, 2025 / Vicore Pharma Holding AB (publ) (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs......
20.11.25 - 08:30
Vicore Pharma Holding: Vicore to Present at the DNB Carnegie Nordic Healthcare Conference (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / November 20, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs)......
17.11.25 - 08:30
Vicore Pharma Holding: Vicore to Present at The Jefferies Global Healthcare Conference in London (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / November 17, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs)......
05.11.25 - 09:06
Vicore Pharma Holding: Vicore to Present at Upcoming Investor Conferences (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / November 5, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today ......
05.11.25 - 08:30
Vicore Pharma Holding: Interim Report July - September 2025 (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / November 5, 2025 / Vicore Pharma Holding (STO:VICO) - Stockholm, November 5, 2025 - Vicore Pharma Holding AB (STO:VICO) unlocking the potential of a novel class of......
03.11.25 - 10:30
Vicore Pharma Holding: Vicore Announces The Nomination Committee For The 2026 Annual General Meeting (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / November 3, 2025 / Vicore Pharma Holding (STO:VICO) - Stockholm, November 3, 2025 - Vicore Pharma Holding AB (publ)(STO:VICO), unlocking the potential of a novel c......
30.09.25 - 09:06
Vicore Pharma Holding: Buloxibutid Receives Orphan Drug Designation in Japan for the Treatment of Idiopathic Pulmonary Fibrosis (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / September 30, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), toda......
23.09.25 - 08:30
Vicore Pharma Holding: Vicore Announces Presentations at the European Respiratory Society Congress 2025 (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / September 23, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), toda......
15.09.25 - 08:30
Vicore Pharma Holding: Vicore to Present at Pareto Securities′ 16th Annual Healthcare Conference (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / September 15, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), toda......
28.08.25 - 08:30
Vicore Pharma Holding: Vicore to Present at Upcoming Investor Conferences (Accesswire)
 
STOCKHOLM, SE / ACCESS Newswire / August 28, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today a......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!